Please login to the form below

Not currently logged in
Email:
Password:

Pfizer tries to quash Trovan report in Nigeria

Pfizer initiates legal action in Nigerian Federal high court to quash a report by the Investigating Committee on Trovan

Pfizer has initiated a legal action in the Abuja division of the Nigerian Federal high court to quash a report by the Investigating Committee on the Trovan (trovafloxacin) clinical trial conducted in Kano state in 1996.

The government had charged Pfizer and eight others with alleged criminal application of trovafloxacin on 200 Nigerian children. The trial, it is alleged, killed many of the children and left others with various permanent disabilities.

The new Pfizer suit has demanded an order of certiorari (a type of writ seeking judicial review) and the action was assigned to Justice Anwuri Chikere for trial.

If successful, the certiorari could nullify the multiple criminal and civil actions against Pfizer Nigeria and individuals Isa Dutse, Scott Hopkins, Debra Williams, Mike Dunne, Samuel Ohuabunwa, Robert Buhl and William Steere, all of whom face a total 23-count charge.

The high court judge had granted Pfizer an extension of time to apply for leave to challenge the report. The accused could not be arraigned as they were not in court at the last adjourned date.

31st July 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....